Contineum Therapeutics, Inc. (CTNM)
$8.57-35.95%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $320M
- Beta
- 0.75
- P/E (TTM)
- -7.31
- Short % float
- 11.05%
- Days to cover
- 3.6
- SI change
- +25.5%
- 1W
- -32.63%
- 1M
- -42.17%
- vs SPY 1W
- -33.05%
- vs SPY 1M
- -44.23%
Industry peers
FMP comparable companies · ranked by market cap
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.4BCRISISQ 25$29.85-1.63%
- GHRSSELLGH Research PLC$1.4BCRISISQ 15$20.45-5.16%
- LBRXSELLLB Pharmaceuticals Inc Common Stock$992MCRISISQ 78$34.61-3.47%
- SPTXSELLSeaport Therapeutics, Inc. Common Stock$959MQ -7$17.91-5.51%
- ANROSELLAlto Neuroscience, Inc.$843MCRISISQ 17$24.03-0.90%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on CTNM?
- LOPJLB’s latest quantitative signal on Contineum Therapeutics, Inc. (CTNM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CTNM in?
- Contineum Therapeutics, Inc. (CTNM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Contineum Therapeutics, Inc. (CTNM) do?
- Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The companyâs lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary …